3 Beaten-Down Biotech Stocks to Buy Right Now
Biotech stocks that crater on negative clinical results or unfavorable regulatory developments can sometimes represent outstanding investing opportunities. Not all beaten-down biotech stocks, though, are diamonds in the rough.
Among the 15 biotech companies that saw their shares slide by more than 10% last month, for instance, I'd personally only consider buying shares of three: Intercept Pharmaceuticals (NASDAQ: ICPT), Exelixis (NASDAQ: EXEL), and Sage Therapeutics (NASDAQ: SAGE). Here's why.
Image Source: Getty Images.
Source: Fool.com
Exelixis Inc. Stock
€45.21
1.560%
We see a rather positive sentiment for Exelixis Inc. with 17 Buy predictions and 1 Sell predictions.
However, we have a potential of -4.88% for Exelixis Inc. as the target price of 43 € is below the current price of 45.21 €.
